{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:07:25Z","timestamp":1761620845370},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,11,25]],"date-time":"2003-11-25T00:00:00Z","timestamp":1069718400000},"content-version":"vor","delay-in-days":2338,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[1997,7]]},"abstract":"<jats:p><jats:bold>Summary. <\/jats:bold> To determine adverse events of ribavirin in the treatment of chronic hepatitis C, 41 patients (18 with cirrhosis), treated with ribavirin at an initial dose of 600\u20131200mg day<jats:sup>\u20101<\/jats:sup>, were analysed retrospectively (six patients were treated twice because adverse effects during the first treatment necessitated cessation of ribavirin). Indications for ribavirin included a contraindication (<jats:italic>n<\/jats:italic>= 15) an intolerance (<jats:italic>n<\/jats:italic>= 11) or a non\u2010response (<jats:italic>n<\/jats:italic>= 15) to interferon (IFN). Ribavirin was combined with IFN 3 million units (MU) three times weekly for 15 patients and with azathioprine for six patients (five of whom were transplant patients). No cirrhotics and only one patient treated with ribavirin + IFN received azathioprine. The mean duration of treatment was 5 months (range 1\u201318 months). Sixteen of 47 treatments (34%) with ribavirin were stopped: four because of vomiting (8.5%), two for psychiatric disorder, one for dry cough, one for an unrelated cause, and eight (at 1\u20132 months) because of a fall in the level of haemoglobin (Hb) of 4.6 g dl<jats:sup>\u20101<\/jats:sup> (range 2.7\u20135.9 gdl<jats:sup>\u20101<\/jats:sup>); however, according to the rules of international protocol, we would have expected only four treatments (two in patients receiving azathioprine) with Hb &lt; 8.5 g dl<jats:sup>\u20101<\/jats:sup> to be stopped. The decrease in Hb level occurred more slowly in patients treated with IFN plus ribavirin than in patients treated with ribavirin alone and was of lower clinical significance in patients with cirrhosis than in patients without cirrhosis. After exclusion of patients receiving azathioprine, there was no significant difference in the fall of Hb level between cirrhotic and non\u2010cirrhotic patients and between patients treated with IFN plus ribavirin and patients treated with ribavirin alone. Interestingly, the platelet count of patients treated with IFN plus ribavirin fell less than in patients treated with IFN alone. The most important and expected adverse event associated with ribavirin was haemolysis. Anaemia &lt; 8.5 g dl<jats:sup>\u20101<\/jats:sup>, requiring cessation of ribavirin therapy, was present in 9% of patients and was worsened by azathioprine. Abdominal discomfort and dry cough were other, potentially important, clinical adverse events found in our study.<\/jats:p>","DOI":"10.1046\/j.1365-2893.1997.00051.x","type":"journal-article","created":{"date-parts":[[2003,11,26]],"date-time":"2003-11-26T01:19:41Z","timestamp":1069809581000},"page":"243-253","source":"Crossref","is-referenced-by-count":8,"title":["Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin"],"prefix":"10.1111","volume":"4","author":[{"given":"T.","family":"Thevenot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Moussalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Plassart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Blot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Opolon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Poynard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,25]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212313272702"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.510240405","article-title":"Meta\u2010analysis of interferon randomised trials in the treatment of viral hepatitis C. Effects of dose and duration","volume":"24","author":"Poynard T.","year":"1996","journal-title":"Hepatology"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0889-8553(21)00156-4","article-title":"Therapy for chronic hepatitis C","volume":"23","author":"Davis GL","year":"1994","journal-title":"Gastroenterol Clin N Am"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.177.4050.705"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.6.1139"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91707-2"},{"issue":"2","key":"e_1_2_1_8_2","first-page":"13","article-title":"Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non\u2010responders: Italian experience","volume":"23","author":"Brillanti S.","year":"1995","journal-title":"J Hepatol"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840160307"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890410203"},{"key":"e_1_2_1_11_2","first-page":"440A","article-title":"Results of a placebo\u2010controlled study of ribavirin in patients with chronic hepatitis C","volume":"20","author":"Dusheiko G.","year":"1994","journal-title":"Hepatology"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80550-1"},{"issue":"2","key":"e_1_2_1_13_2","first-page":"8","article-title":"The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C","volume":"23","author":"Chemello L.","year":"1995","journal-title":"J Hepatol"},{"issue":"1","key":"e_1_2_1_14_2","first-page":"21","article-title":"What options are left when hepatitis C does not respond to interferon? Placebo\u2010controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon","author":"Brouwer JT","year":"1994","journal-title":"J Hepatol"},{"key":"e_1_2_1_15_2","first-page":"4A","article-title":"Randomized, double blind placebo\u2010controlled trial of ribavirin therapy for chronic hepatitis C","volume":"18","author":"Bisceglie A.","year":"1993","journal-title":"Hepatology"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840200104"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840180206"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90727-T"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040523"},{"key":"e_1_2_1_20_2","first-page":"377","article-title":"Macrocytosis and pure RBC anemia caused by azathicprine","volume":"134","author":"DeClerek YA","year":"1980","journal-title":"Am J Dis Child"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02333.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.47.6.503"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.1995.tb01709.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)28434-6"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80626-9"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(93)91887-X"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(95)94885-6"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2893.1997.00051.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2893.1997.00051.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T10:58:09Z","timestamp":1698490689000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2893.1997.00051.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["10.1046\/j.1365-2893.1997.00051.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2893.1997.00051.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}